PX1 Research provides certified, high-purity Follistatin research compounds tailored for rigorous in vitro and preclinical research applications. Every lot undergoes independent analytical validation to guarantee structural integrity, exact sequence mass, and low endotoxin levels for reliable laboratory data.
PX1 Research provides certified, high-purity Follistatin research compounds tailored for rigorous in vitro and preclinical research applications. Every lot undergoes independent analytical validation to guarantee structural integrity, exact sequence mass, and low endotoxin levels for reliable laboratory data.
When purchasing Follistatin peptide for sale, researchers require high-purity, laboratory-grade material validated by third-party high-performance liquid chromatography (HPLC) and mass spectrometry (MS). PX1 Research supplies USA-manufactured Follistatin as a lyophilized powder, strictly intended for in vitro assays and preclinical animal models. Each batch includes a lot-specific Certificate of Analysis (COA) confirming purity, molecular weight, and endotoxin levels.
Sourcing high-purity research compounds from certified domestic suppliers eliminates cross-contamination risks and batch-to-batch variability. PX1 Research manufactures all compounds in state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards, ensuring consistent experimental reproducibility across all cellular and biochemical inquiries.
Follistatin (FST) is an autocrine glycoprotein expressed in nearly all vascularized animal tissues. Identified originally as an inhibitor of follicle-stimulating hormone (FSH) secretion from the anterior pituitary, subsequent structural analysis established Follistatin as a potent biological antagonist to specific members of the Transforming Growth Factor-beta (TGF-β) superfamily.
The molecular structure of Follistatin contains three domain repeats (FSD1, FSD2, and FSD3) rich in cysteine residues that facilitate intricate disulfide bonding patterns. Preclinical investigations focus primarily on distinct isoforms derived from alternative splicing and post-translational processing, including Follistatin-288 (FS-288), Follistatin-300 (FS-300), and Follistatin-315 (FS-315). Furthermore, engineered variants such as Follistatin-344 serve as common standard reagents in experimental protocols examining localized versus systemic ligand sequestration.
In cell culture models, the binding affinity of Follistatin for target ligands is governed by its basic N-terminal domain. Structural biology studies show that a single Follistatin dimer encapsulates target ligands, effectively blocking their interaction with type II activin receptor complexes (ActRIIA and ActRIIB).
The primary mechanism of action for Follistatin involves high-affinity sequestration of activin A, activin B, and myostatin (Growth Differentiation Factor 8, or GDF-8). In vitro binding assays indicate that Follistatin binds myostatin with nanomolar affinity, preventing myostatin from engaging ActRIIB receptors on the cell surface.
Under baseline physiological conditions, activation of the ActRIIB complex initiates a signaling cascade that phosphorylates Smad2 and Smad3 transcription factors. Activated Smad2/3 complexes translocate to the nucleus, upregulating genes that repress protein synthesis and promote muscle proteolysis via the ubiquitin-proteasome pathway. By binding circulating or localized myostatin, Follistatin suppresses Smad2/3 phosphorylation.
Consequently, preclinical studies suggest that Follistatin-mediated inhibition of Smad signaling releases the brake on the Akt/mTOR (mammalian target of rapamycin) pathway. This permits uninhibited translational machinery engagement, promoting cellular hypertrophy, protein synthesis, and enhanced satellite cell proliferation in culture systems and animal tissue models.
In vitro data indicate that Follistatin administration in skeletal muscle cell cultures leads to increased myotube diameter and fusion indices. Researchers utilize Follistatin to explore regulatory networks governing myogenesis, satellite cell activation, and microRNA transcription during muscle cell differentiation.
In rodent models of muscle wasting, such as sarcopenia, muscular dystrophy, or cancer cachexia, experimental treatment with Follistatin isoforms has demonstrated significant restoration of cross-sectional muscle area and force generation capabilities. Animal studies reveal that Follistatin administration can mitigate muscle loss even under conditions of severe catabolic stress or denervation.
Beyond skeletal muscle, preclinical investigation highlights Follistatin's role in fibrotic tissue remodeling. Because activin A acts as a pro-fibrotic cytokine in pulmonary, hepatic, and renal tissues, Follistatin antagonism has been shown to reduce collagen deposition and downregulate alpha-smooth muscle actin (α-SMA) expression in preclinical models of organ fibrosis. Researchers investigating broader tissue repair mechanisms can review our selection across all peptides for complementary experimental reagents.
To understand signaling pathways related to tissue growth and hypertrophy, laboratory researchers frequently compare Follistatin against other targeted research peptides. While Follistatin operates primarily through direct ligand neutralisation within the TGF-β superfamily, agents such as IGF-1 LR3 promote cellular proliferation via receptor tyrosine kinase phosphorylation and activation of the MAPK/ERK pathway. Comparing these mechanisms side-by-side allows investigators to dissect independent versus convergent anabolic cascades in cell culture.
In contrast to systemic metabolic signaling modulators like CJC-1295, which stimulate endogenously secreted growth factors, Follistatin functions downstream as a localized protein antagonist. Additionally, researchers examining cellular repair pathways often compare Follistatin’s anti-fibrotic action to extracellular matrix remodeling compounds like BPC-157. Further comparative analyses of myostatin antagonists and growth factor signaling can be explored in our myostatin inhibitors research review.
Understanding these distinct mechanism classes enables research groups to design optimized multi-variable in vitro trials and evaluate downstream transcriptional changes with maximal accuracy.
When evaluating a supplier when seeking follistatin peptide for sale, rigorous analytical verification is necessary to prevent experimental error. Compromised, impure, or mislabeled peptide products introduce uncontrolled variables that alter receptor binding kinetics and confound quantitative assay results.
PX1 Research enforces strict quality assurance protocols for every product batch:
• Reverse-Phase HPLC (RP-HPLC): Validates chemical purity, ensuring target peptide concentration meets or exceeds 98%. Chromatograms are provided to document peak retention times and isolate impurities.
• Electrospray Ionization Mass Spectrometry (ESI-MS): Verifies exact theoretical molecular mass, confirming correct amino acid sequence synthesis and identifying potential truncation fragments.
• Endotoxin Testing: Assayed via Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels fall strictly below <0.01 EU/μg, preventing non-specific inflammatory signaling in cell culture or animal assays.
• ISO 17025 & GMP Compliance: Synthesized in domestic, GMP-compliant facilities and tested in accredited ISO 17025 analytical laboratories in the USA.
Every standard container shipped by PX1 Research includes batch-matched COAs accessible for institutional audit and data verification. Explore complete chemical catalog standards via our main research hub.
Proper reconstitution and handling of lyophilized Follistatin peptides are essential to maintain secondary and tertiary structural integrity. Hydrophobic regions and cysteine disulfide bonds present in Follistatin make it sensitive to improper physical handling, temperature fluctuations, and pH changes.
To reconstitute Follistatin for in vitro or animal laboratory research, follow established laboratory protocols:
1. Equilibration: Allow the lyophilized vial to reach room temperature before reconstitution to minimize condensation inside the container.
2. Solubilization: Reconstitute using sterile bacteriostatic water or sterile phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear agitation; gently swirl or invert the container until the lyophilized cake fully dissolves.
3. Aliquot Preparation: To prevent repeated freeze-thaw cycles—which degrade peptide bonds and induce aggregation—aliquot the reconstituted solution into sterile microcentrifuge tubes according to planned experimental volumes.
4. Storage Conditions: Store unopened lyophilized vials at -20°C or -80°C for long-term stability. Reconstituted aliquots should be stored at -80°C and used within recommended lab protocol timeframes.
For precise concentration calculations, researchers can utilize our integrated peptide reconstitution calculator.
PX1 Research supports university research departments, biotechnology enterprises, and contract research organizations (CROs) requiring bulk quantities of research-grade Follistatin. We maintain continuous inventory manufactured in domestic facilities, providing reliable lot continuity for long-term study protocols.
Orders placed Monday through Friday ship same-day from our fulfillment facilities located in California and Arizona. For institutional pricing, customized packaging, or dedicated bulk batch synthesis, research teams can submit inquiry details directly through our wholesale laboratory account portal.
What is the primary scientific application of Follistatin in research?
Follistatin is primarily studied in preclinical and in vitro research as an autocrine glycoprotein that antagonizes TGF-β superfamily ligands, specifically activin A and myostatin (GDF-8), to investigate skeletal muscle hypertrophy, satellite cell differentiation, and anti-fibrotic pathways.
How does PX1 Research verify the purity of Follistatin peptide?
PX1 Research verifies each lot of Follistatin through third-party ISO 17025 accredited testing using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm purity (≥98%) and Electrospray Ionization Mass Spectrometry (ESI-MS) to confirm correct molecular weight.
What are the endotoxin limits for PX1 Research Follistatin?
All Follistatin research compounds from PX1 Research undergo LAL testing to ensure endotoxin levels remain below 0.01 EU/μg, protecting cell cultures and experimental animal models from non-specific inflammatory responses.
How should lyophilized Follistatin be stored upon delivery?
Unopened, lyophilized Follistatin should be stored at -20°C or -80°C in a dry environment protected from light. Upon reconstitution with sterile solvent, the solution should be aliquoted and maintained at -80°C to prevent freeze-thaw degradation.
What is the difference between Follistatin-344 and Follistatin-315 in preclinical literature?
Follistatin-344 is a precursor peptide that undergoes post-translational modification to form circulating isoforms like Follistatin-315. In research settings, specific isoforms or precursor sequences are selected based on tissue-binding affinity and systemic half-life targets in animal models.
Where is PX1 Research Follistatin manufactured and shipped from?
PX1 Research compounds are synthesized in domestic US facilities compliant with GMP standards and shipped same-day (Monday–Friday) from dispatch hubs in California and Arizona.
Can Follistatin be purchased for clinical or personal human use?
No. Follistatin provided by PX1 Research is strictly sold as a research compound for laboratory, in vitro, and preclinical experimental applications. It is not for human, clinical, therapeutic, or diagnostic use.
How can institutional laboratories arrange bulk orders of Follistatin?
Institutional researchers and laboratory procurement officers can request volume pricing, lot reservation, and dedicated batch documentation through the PX1 Research wholesale portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.